alogliptin + rapid-acting insulin secretagogue

**Alogliptin + rapid-acting insulin secretagogue** is a combination regimen used in the management of type 2 diabetes mellitus for patients with inadequate glycemic control despite therapy with a rapid-acting insulin secretagogue, diet, and exercise. **Alogliptin** is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases endogenous incretin hormones (GLP-1 and GIP), resulting in glucose-dependent stimulation of insulin secretion and inhibition of glucagon release. **Rapid-acting insulin secretagogues**—such as meglitinide analogues (e.g., repaglinide, nateglinide)—stimulate pancreatic β-cells to release insulin by closing ATP-sensitive potassium channels, thereby increasing insulin secretion predominantly in response to meals and reducing postprandial hyperglycemia. The combination aims to improve glycemic control by targeting different mechanisms: alogliptin enhances incretin effect while the secretagogue increases meal-time insulin secretion. This combination has been clinically studied as an add-on approach for patients not adequately controlled on secretagogue monotherapy[1][7].